1
|
Nurminen A, Jaatinen S, Taavitsainen S, Högnäs G, Lesluyes T, Ansari-Pour N, Tolonen T, Haase K, Koskenalho A, Kankainen M, Jasu J, Rauhala H, Kesäniemi J, Nikupaavola T, Kujala P, Rinta-Kiikka I, Riikonen J, Kaipia A, Murtola T, Tammela TL, Visakorpi T, Nykter M, Wedge DC, Van Loo P, Bova GS. Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine. Genome Med 2023; 15:82. [PMID: 37828555 PMCID: PMC10571458 DOI: 10.1186/s13073-023-01242-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Accepted: 10/02/2023] [Indexed: 10/14/2023] Open
Abstract
BACKGROUND Prostate cancer (PrCa) genomic heterogeneity causes resistance to therapies such as androgen deprivation. Such heterogeneity can be deciphered in the context of evolutionary principles, but current clinical trials do not include evolution as an essential feature. Whether or not analysis of genomic data in an evolutionary context in primary prostate cancer can provide unique added value in the research and clinical domains remains an open question. METHODS We used novel processing techniques to obtain whole genome data together with 3D anatomic and histomorphologic analysis in two men (GP5 and GP12) with high-risk PrCa undergoing radical prostatectomy. A total of 22 whole genome-sequenced sites (16 primary cancer foci and 6 lymph node metastatic) were analyzed using evolutionary reconstruction tools and spatio-evolutionary models. Probability models were used to trace spatial and chronological origins of the primary tumor and metastases, chart their genetic drivers, and distinguish metastatic and non-metastatic subclones. RESULTS In patient GP5, CDK12 inactivation was among the first mutations, leading to a PrCa tandem duplicator phenotype and initiating the cancer around age 50, followed by rapid cancer evolution after age 57, and metastasis around age 59, 5 years prior to prostatectomy. In patient GP12, accelerated cancer progression was detected after age 54, and metastasis occurred around age 56, 3 years prior to prostatectomy. Multiple metastasis-originating events were identified in each patient and tracked anatomically. Metastasis from prostate to lymph nodes occurred strictly ipsilaterally in all 12 detected events. In this pilot, metastatic subclone content analysis appears to substantially enhance the identification of key drivers. Evolutionary analysis' potential impact on therapy selection appears positive in these pilot cases. CONCLUSIONS PrCa evolutionary analysis allows tracking of anatomic site of origin, timing of cancer origin and spread, and distinction of metastatic-capable from non-metastatic subclones. This enables better identification of actionable targets for therapy. If extended to larger cohorts, it appears likely that similar analyses could add substantial biological insight and clinically relevant value.
Collapse
Affiliation(s)
- Anssi Nurminen
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, PO Box 100, 33014, Tampere, Finland
| | - Serafiina Jaatinen
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, PO Box 100, 33014, Tampere, Finland
| | - Sinja Taavitsainen
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, PO Box 100, 33014, Tampere, Finland
| | - Gunilla Högnäs
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, PO Box 100, 33014, Tampere, Finland
| | - Tom Lesluyes
- The Francis Crick Institute, London, NW1 1AT, UK
| | - Naser Ansari-Pour
- MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
| | - Teemu Tolonen
- Fimlab Laboratories, Department of Pathology, Tampere University Hospital, Tampere, Finland
| | - Kerstin Haase
- The Francis Crick Institute, London, NW1 1AT, UK
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität Zu Berlin, ECRC Experimental and Clinical Research Center, Berlin, Germany
| | - Antti Koskenalho
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, PO Box 100, 33014, Tampere, Finland
| | - Matti Kankainen
- Institute for Molecular Medicine Finland, University of Helsinki, Tukholmankatu 8, Helsinki, 00290, Finland
| | - Juho Jasu
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, PO Box 100, 33014, Tampere, Finland
| | - Hanna Rauhala
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, PO Box 100, 33014, Tampere, Finland
| | - Jenni Kesäniemi
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, PO Box 100, 33014, Tampere, Finland
| | - Tiia Nikupaavola
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, PO Box 100, 33014, Tampere, Finland
| | - Paula Kujala
- Fimlab Laboratories, Department of Pathology, Tampere University Hospital, Tampere, Finland
| | - Irina Rinta-Kiikka
- Imaging Centre, Department of Radiology, Tampere University Hospital, Tampere, Finland
| | - Jarno Riikonen
- Department of Urology, TAYS Cancer Center, Tampere University Hospital, Tampere, Finland
| | - Antti Kaipia
- Department of Urology, TAYS Cancer Center, Tampere University Hospital, Tampere, Finland
| | - Teemu Murtola
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, PO Box 100, 33014, Tampere, Finland
- Department of Urology, TAYS Cancer Center, Tampere University Hospital, Tampere, Finland
| | - Teuvo L Tammela
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, PO Box 100, 33014, Tampere, Finland
- Department of Urology, TAYS Cancer Center, Tampere University Hospital, Tampere, Finland
| | - Tapio Visakorpi
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, PO Box 100, 33014, Tampere, Finland
- Fimlab Laboratories, Department of Pathology, Tampere University Hospital, Tampere, Finland
| | - Matti Nykter
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, PO Box 100, 33014, Tampere, Finland
| | - David C Wedge
- Manchester Cancer Research Centre, Division of Cancer Sciences, University of Manchester, Manchester, M20 4GJ, UK
| | - Peter Van Loo
- The Francis Crick Institute, London, NW1 1AT, UK
- Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
| | - G Steven Bova
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, PO Box 100, 33014, Tampere, Finland.
| |
Collapse
|
2
|
Jasu J, Tolonen T, Antonarakis ES, Beltran H, Halabi S, Eisenberger MA, Carducci MA, Loriot Y, Van der Eecken K, Lolkema M, Ryan CJ, Taavitsainen S, Gillessen S, Högnäs G, Talvitie T, Taylor RJ, Koskenalho A, Ost P, Murtola TJ, Rinta-Kiikka I, Tammela T, Auvinen A, Kujala P, Smith TJ, Kellokumpu-Lehtinen PL, Isaacs WB, Nykter M, Kesseli J, Bova GS. Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. EUR UROL SUPPL 2021; 30:47-62. [PMID: 34337548 PMCID: PMC8317817 DOI: 10.1016/j.euros.2021.05.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/27/2021] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Systematic identification of data essential for outcome prediction in metastatic prostate cancer (mPC) would accelerate development of precision oncology. OBJECTIVE To identify novel phenotypes and features associated with mPC outcome, and to identify biomarker and data requirements to be tested in future precision oncology trials. DESIGN SETTING AND PARTICIPANTS We analyzed deep longitudinal clinical, neuroendocrine expression, and autopsy data of 33 men who died from mPC between 1995 and 2004 (PELICAN33), and related findings to mPC biomarkers reported in the literature. INTERVENTION Thirty-three men prospectively consented to participate in an integrated clinical-molecular rapid autopsy study of mPC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Data exploration with correction for multiple testing and survival analysis from the time of diagnosis to time to death and time to first occurrence of severe pain as outcomes were carried out. The effect of seven complications on the modeled probability of dying within 2 yr after presenting with the complication was evaluated using logistic regression. RESULTS AND LIMITATIONS Feature exploration revealed novel phenotypes related to mPC outcome. Four complications (pleural effusion, severe anemia, severe or controlled pain, and bone fracture) predict the likelihood of death within 2 yr. Men with Gleason grade group 5 cancers developed severe pain sooner than those with lower-grade tumors. Surprisingly, neuroendocrine (NE) differentiation was frequently observed in the setting of high serum prostate-specific antigen (PSA) levels (≥30 ng/ml). In 4/33 patients, no controlled (requiring analgesics) or severe pain was detected, and strikingly, 14/15 metastatic sites studied in these men did not express NE markers, suggesting an inverse relationship between NE differentiation and pain in mPC. Intracranial subdural metastasis is common (36%) and is usually clinically undetected. Categorization of "skeletal-related events" complications used in recent studies likely obscures the understanding of spinal cord compression and fracture. Early death from prostate cancer was identified in a subgroup of men with a low longitudinal PSA bandwidth. Cachexia is common (body mass index <0.89 in 24/31 patients) but limited to the last year of life. Biomarker review identified 30 categories of mPC biomarkers in need of winnowing in future trials. All findings require validation in larger cohorts, preferably alongside data from this study. CONCLUSIONS The study identified novel outcome subgroups for future validation and provides "vision for mPC precision oncology 2020-2050" draft recommendations for future data collection and biomarker studies. PATIENT SUMMARY To better understand variation in metastatic prostate cancer behavior, we assembled and analyzed longitudinal clinical and autopsy records in 33 men. We identified novel outcomes, phenotypes, and aspects of disease burden to be tested and refined in future trials.
Collapse
Affiliation(s)
- Juho Jasu
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, Tampere, FI-33014, Finland
| | - Teemu Tolonen
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, Tampere, FI-33014, Finland
- Fimlab Laboratories, Department of Pathology, Tampere University Hospital, Tampere, Finland
| | - Emmanuel S. Antonarakis
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
| | | | - Susan Halabi
- Duke University Medical Center, Department of Biostatistics and Bioinformatics, Durham, NC, USA
| | - Mario A. Eisenberger
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
| | - Michael A. Carducci
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
| | - Yohann Loriot
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | - Kim Van der Eecken
- Department of Medical and Forensic Pathology, Ghent University, Ghent, Belgium
| | - Martijn Lolkema
- Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Charles J. Ryan
- Department of Medicine, Division of Oncology, University of Minnesota, Minneapolis, MN, USA
| | - Sinja Taavitsainen
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, Tampere, FI-33014, Finland
| | - Silke Gillessen
- Institute of Oncology of Southern Switzerland, Bellinzona, Switzerland
- Faculty of Biosciences, Università della Svizzera Italiana, Lugano, Switzerland
- Faculty of Cancer Science, University of Manchester, UK
| | - Gunilla Högnäs
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, Tampere, FI-33014, Finland
| | - Timo Talvitie
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, Tampere, FI-33014, Finland
| | | | - Antti Koskenalho
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, Tampere, FI-33014, Finland
| | - Piet Ost
- Department of Radiation Oncology, Iridium Netwerk, Wilrijk (Antwerp), Belgium
- Department of Human Structure and Repair, Ghent University, Ghent, Belgium
| | - Teemu J. Murtola
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, Tampere, FI-33014, Finland
- TAYS Cancer Center, Department of Urology, Tampere, Finland
| | - Irina Rinta-Kiikka
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, Tampere, FI-33014, Finland
- TAYS Cancer Center, Department of Radiology, Tampere, Finland
| | - Teuvo Tammela
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, Tampere, FI-33014, Finland
- TAYS Cancer Center, Department of Urology, Tampere, Finland
| | - Anssi Auvinen
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, Tampere, FI-33014, Finland
- Faculty of Social Sciences, Unit of Health Sciences, Tampere University, Tampere, Finland
| | - Paula Kujala
- Fimlab Laboratories, Department of Pathology, Tampere University Hospital, Tampere, Finland
| | - Thomas J. Smith
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
| | - Pirkko-Liisa Kellokumpu-Lehtinen
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, Tampere, FI-33014, Finland
| | - William B. Isaacs
- Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
| | - Matti Nykter
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, Tampere, FI-33014, Finland
| | - Juha Kesseli
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, Tampere, FI-33014, Finland
| | - G. Steven Bova
- Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, Tampere, FI-33014, Finland
| |
Collapse
|
3
|
Högnäs G, Kivinummi K, Kallio HML, Hieta R, Ruusuvuori P, Koskenalho A, Kesseli J, Tammela TLJ, Riikonen J, Ilvesaro J, Kares S, Hirvikoski PP, Laurila M, Mirtti T, Nykter M, Kujala PM, Visakorpi T, Tolonen T, Bova GS. Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues. Am J Surg Pathol 2017; 42:103-115. [PMID: 28984675 DOI: 10.1097/pas.0000000000000961] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Advances in prostate cancer biology and diagnostics are dependent upon high-fidelity integration of clinical, histomorphologic, and molecular phenotypic findings. In this study, we compared fresh frozen, formalin-fixed paraffin-embedded (FFPE), and PAXgene-fixed paraffin-embedded (PFPE) tissue preparation methods in radical prostatectomy prostate tissue from 36 patients and performed a preliminary test of feasibility of using PFPE tissue in routine prostate surgical pathology diagnostic assessment. In addition to comparing histology, immunohistochemistry, and general measures of DNA and RNA integrity in each fixation method, we performed functional tests of DNA and RNA quality, including targeted Miseq RNA and DNA sequencing, and implemented methods to relate DNA and RNA yield and quality to quantified DNA and RNA picogram nuclear content in each tissue volume studied. Our results suggest that it is feasible to use PFPE tissue for routine robot-assisted laparoscopic prostatectomy surgical pathology diagnostics and immunohistochemistry, with the benefit of significantly improvedDNA and RNA quality and RNA picogram yield per nucleus as compared with FFPE tissue. For fresh frozen, FFPE, and PFPE tissues, respectively, the average Genomic Quality Numbers were 7.9, 3.2, and 6.2, average RNA Quality Numbers were 8.7, 2.6, and 6.3, average DNA picogram yields per nucleus were 0.41, 0.69, and 0.78, and average RNA picogram yields per nucleus were 1.40, 0.94, and 2.24. These findings suggest that where DNA and/or RNA analysis of tissue is required, and when tissue size is small, PFPE may provide important advantages over FFPE. The results also suggest several interesting nuances including potential avenues to improve RNA quality in FFPE tissues and confirm recent suggestions that some DNA sequence artifacts associated with FFPE can be avoided.
Collapse
Affiliation(s)
- Gunilla Högnäs
- Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute
| | - Kati Kivinummi
- Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute
| | - Heini M L Kallio
- Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute
| | - Reija Hieta
- Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute
| | - Pekka Ruusuvuori
- Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute.,Signal Processing Laboratory, Tampere University of Technology, Pori
| | - Antti Koskenalho
- Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute
| | - Juha Kesseli
- Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute
| | - Teuvo L J Tammela
- Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute.,Department of Urology, University of Tampere
| | | | - Joanna Ilvesaro
- Fimlab Laboratories, Department of Pathology, Tampere University Hospital, Tampere
| | - Saara Kares
- Fimlab Laboratories, Department of Pathology, Tampere University Hospital, Tampere
| | | | - Marita Laurila
- Fimlab Laboratories, Department of Pathology, Tampere University Hospital, Tampere
| | - Tuomas Mirtti
- Institute for Molecular Medicine Finland, University of Helsinki.,Department of Pathology, HUSLAB, Helsinki University Hospital, Helsinki, Finland
| | - Matti Nykter
- Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute
| | - Paula M Kujala
- Fimlab Laboratories, Department of Pathology, Tampere University Hospital, Tampere
| | - Tapio Visakorpi
- Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute.,Fimlab Laboratories, Department of Pathology, Tampere University Hospital, Tampere
| | - Teemu Tolonen
- Fimlab Laboratories, Department of Pathology, Tampere University Hospital, Tampere
| | - G Steven Bova
- Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute
| |
Collapse
|
4
|
Bova GS, Kallio HML, Annala M, Kivinummi K, Högnäs G, Häyrynen S, Rantapero T, Kivinen V, Isaacs WB, Tolonen T, Nykter M, Visakorpi T. Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer. Cold Spring Harb Mol Case Stud 2016; 2:a000752. [PMID: 27148588 PMCID: PMC4853517 DOI: 10.1101/mcs.a000752] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
We report the first combined analysis of whole-genome sequence, detailed clinical history, and transcriptome sequence of multiple prostate cancer metastases in a single patient (A21). Whole-genome and transcriptome sequence was obtained from nine anatomically separate metastases, and targeted DNA sequencing was performed in cancerous and noncancerous foci within the primary tumor specimen removed 5 yr before death. Transcriptome analysis revealed increased expression of androgen receptor (AR)-regulated genes in liver metastases that harbored an AR p.L702H mutation, suggesting a dominant effect by the mutation despite being present in only one of an estimated 16 copies per cell. The metastases harbored several alterations to the PI3K/AKT pathway, including a clonal truncal mutation in PIK3CG and present in all metastatic sites studied. The list of truncal genomic alterations shared by all metastases included homozygous deletion of TP53, hemizygous deletion of RB1 and CHD1, and amplification of FGFR1. If the patient were treated today, given this knowledge, the use of second-generation androgen-directed therapies, cessation of glucocorticoid administration, and therapeutic inhibition of the PI3K/AKT pathway or FGFR1 receptor could provide personalized benefit. Three previously unreported truncal clonal missense mutations (ABCC4 p.R891L, ALDH9A1 p.W89R, and ASNA1 p.P75R) were expressed at the RNA level and assessed as druggable. The truncal status of mutations may be critical for effective actionability and merit further study. Our findings suggest that a large set of deeply analyzed cases could serve as a powerful guide to more effective prostate cancer basic science and personalized cancer medicine clinical trials.
Collapse
Affiliation(s)
- G Steven Bova
- Prostate Cancer Research Center, Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, FI-33014 Tampere, Finland
| | - Heini M L Kallio
- Prostate Cancer Research Center, Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, FI-33014 Tampere, Finland
| | - Matti Annala
- Prostate Cancer Research Center, Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, FI-33014 Tampere, Finland
| | - Kati Kivinummi
- Prostate Cancer Research Center, Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, FI-33014 Tampere, Finland
| | - Gunilla Högnäs
- Prostate Cancer Research Center, Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, FI-33014 Tampere, Finland
| | - Sergei Häyrynen
- Prostate Cancer Research Center, Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, FI-33014 Tampere, Finland
| | - Tommi Rantapero
- Prostate Cancer Research Center, Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, FI-33014 Tampere, Finland
| | - Virpi Kivinen
- Prostate Cancer Research Center, Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, FI-33014 Tampere, Finland
| | - William B Isaacs
- The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
| | - Teemu Tolonen
- Prostate Cancer Research Center, Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, FI-33014 Tampere, Finland
| | - Matti Nykter
- Prostate Cancer Research Center, Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, FI-33014 Tampere, Finland
| | - Tapio Visakorpi
- Prostate Cancer Research Center, Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, FI-33014 Tampere, Finland
| |
Collapse
|
5
|
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio H, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS. Abstract 956: The evolutionary history of lethal metastatic prostate cancer. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-956] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cancers emerge from an on-going Darwinian evolutionary process, often leading to multiple competing subclones within a single primary tumour. This evolutionary process culminates in the formation of metastases, which is the cause of 90% of cancer-related deaths. However, despite its clinical importance, little is known about the principles governing the dissemination of cancer cells to distant organs. Although the hypothesis that each metastasis originates from a single tumour cell is generally supported, recent studies using mouse models of cancer demonstrated the existence of polyclonal seeding from and inter-clonal cooperation between multiple subclones. In this study, we sought definitive evidence for the existence of polyclonal seeding in human malignancy and to establish the clonal relationship among different metastases in the context of androgen-deprived metastatic prostate cancer. Using whole genome sequencing, we characterised multiple metastases arising from prostate tumours in ten patients. Integrated analyses of subclonal architecture revealed the patterns of metastatic spread in unprecedented detail. Metastasis-to-metastasis spread was found to be common, either through de novo monoclonal seeding of daughter metastases or, in five cases, through the transfer of multiple tumour clones between metastatic sites. Lesions affecting tumour suppressor genes usually occur as single events, whereas mutations in genes involved in androgen receptor signalling commonly involve multiple, convergent events in different metastases. Our results elucidate in detail the complex patterns of metastatic spread and further our understanding of the development of resistance to androgen deprivation therapy in prostate cancer.
Citation Format: Gunes Gundem, Peter Van Loo, Barbara Kremeyer, Ludmil B. Alexandrov, Jose M.C. Tubio, Elli Papaemmanuil, Daniel S. Brewer, Heini Kallio, Gunilla Högnäs, Matti Annala, Kati Kivinummi, Victoria Goody, Calli Latimer, Sarah O'Meara, Kevin J. Dawson, William Isaacs, Michael R. Emmert-Buck, Matti Nykter, Christopher Foster, Zsofia Kote-Jarai, Douglas Easton, Hayley C. Whitaker, David E. Neal, Colin S. Cooper, Rosalind A. Eeles, Tapio Visakorpi, Peter J. Campbell, Ultan McDermott, David C. Wedge, G. S. Bova. The evolutionary history of lethal metastatic prostate cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 956. doi:10.1158/1538-7445.AM2015-956
Collapse
Affiliation(s)
- Gunes Gundem
- 1Wellcome Trust Sanger Institute, Hinxton, United Kingdom
| | - Peter Van Loo
- 1Wellcome Trust Sanger Institute, Hinxton, United Kingdom
| | | | | | | | | | - Daniel S. Brewer
- 2Norwich Medical School and Department of Biological Sciences, University of East Anglia, Norwich, United Kingdom
| | - Heini Kallio
- 3Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere, Tampere, Finland
| | - Gunilla Högnäs
- 3Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere, Tampere, Finland
| | - Matti Annala
- 3Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere, Tampere, Finland
| | - Kati Kivinummi
- 3Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere, Tampere, Finland
| | - Victoria Goody
- 1Wellcome Trust Sanger Institute, Hinxton, United Kingdom
| | - Calli Latimer
- 1Wellcome Trust Sanger Institute, Hinxton, United Kingdom
| | - Sarah O'Meara
- 1Wellcome Trust Sanger Institute, Hinxton, United Kingdom
| | | | | | - Michael R. Emmert-Buck
- 5Laboratory of Pathology, National Cancer Institute, National Institutes of Health; Avoneaux Medical Institute, Oxford, MD
| | - Matti Nykter
- 3Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere, Tampere, Finland
| | - Christopher Foster
- 6University of Liverpool and HCA Pathology Laboratories, London, United Kingdom
| | - Zsofia Kote-Jarai
- 7Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom
| | - Douglas Easton
- 8Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom
| | - Hayley C. Whitaker
- 9Uro-oncology Research Group, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom
| | - David E. Neal
- 9Uro-oncology Research Group, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom
| | - Colin S. Cooper
- 10Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, UK; and Norwich Medical School and Department of Biological Sciences, University of East Anglia, Norwich, United Kingdom
| | - Rosalind A. Eeles
- 11Division of Genetics and Epidemiology, The Institute Of Cancer Research; Royal Marsden NHS Foundation Trust, London and Sutton, UK, London, United Kingdom
| | - Tapio Visakorpi
- 3Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere, Tampere, Finland
| | | | | | - David C. Wedge
- 1Wellcome Trust Sanger Institute, Hinxton, United Kingdom
| | - G. S. Bova
- 3Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere, Tampere, Finland
| |
Collapse
|
6
|
Kallio HM, Annala M, Kivinummi K, Högnäs G, Gundem G, Wedge DC, Van Loo P, Heyn H, Emmert-Buck MR, Isaacs WB, Esteller M, McDermott U, Nykter M, Visakorpi T, Bova GS. Abstract 3883: Clonal evolution of a lethal prostate cancer: Integrated whole genome analysis case study. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-3883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Prostate cancer (PC) is prevalent in both indolent and lethal forms. Although many PC patients diagnosed today have organ-confined disease curable by prostatectomy or radiation therapy, 20-30% of PCs will relapse to lethal disease within 5-years of treatment. Relatively little attention has been paid to distinguishing the molecular characteristics of proven lethal metastatic PC from non-lethal cancers. A better understanding of the origins and evolution of lethal cancers should allow screening and treatment to be better tailored to the needs of each patient. To this end, we performed an integrative molecular profiling of a lethal PC from one patient (A21). High-coverage whole genome sequence, transcriptome sequence, and methylation analysis was performed on 9 anatomically separate metastases obtained by autopsy, and targeted sequencing was performed in multiple cancerous and noncancerous foci within the radical prostatectomy specimen removed 5 years prior to death. Molecular results were analyzed in relation to detailed clinical data. Integrated whole genome sequence analysis revealed convergent evolution of AR gene amplification events, and inception of p.L702H mutation in the AR present only in liver metastases. In addition, the analysis showed parallel increases in AR regulated transcripts in the liver metastases, suggesting a dominant effect by the mutation. Mutation of PI3/PI4 kinase member PIK3CG was found in all metastases but in no primary tumor foci studied. The study demonstrated the power of an integrated approach to interrogate clonal evolution of cancer suggesting that such studies are valuable on the individual level and could lead the way towards personalized treatment. In the individual studied, cessation of corticosteroid treatment and/or therapeutic manipulation of PI3K/AKT/mTOR activity theoretically could have provided a personalized benefit. These findings suggest that similar integrated analysis in large cohorts of patients with metastatic cancer could accelerate progress in establishing effective personalized cancer medicine.
Citation Format: Heini M.L. Kallio, Matti Annala, Kati Kivinummi, Gunilla Högnäs, Gunes Gundem, David C. Wedge, Peter Van Loo, Holger Heyn, Michael R. Emmert-Buck, William B. Isaacs, Manel Esteller, Ultan McDermott, Matti Nykter, Tapio Visakorpi, G. Steven Bova. Clonal evolution of a lethal prostate cancer: Integrated whole genome analysis case study. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3883. doi:10.1158/1538-7445.AM2015-3883
Collapse
Affiliation(s)
- Heini M.L. Kallio
- 1Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - Matti Annala
- 1Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - Kati Kivinummi
- 1Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - Gunilla Högnäs
- 1Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - Gunes Gundem
- 2Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
| | - David C. Wedge
- 2Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
| | - Peter Van Loo
- 2Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
| | - Holger Heyn
- 3Cancer Epigenetics and Biology Program (PEBC), Bellvitge Institute for Biomedical Research (IDIBELL), Hospital Duran i Reynals, Barcelona, Spain
| | - Michael R. Emmert-Buck
- 4Laboratory of Pathology, National Cancer Institute, National Institutes of Health, MD, USA. Present Address: Avoneaux Medical Institute, Oxford, MD
| | | | - Manel Esteller
- 3Cancer Epigenetics and Biology Program (PEBC), Bellvitge Institute for Biomedical Research (IDIBELL), Hospital Duran i Reynals, Barcelona, Spain
| | - Ultan McDermott
- 2Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
| | - Matti Nykter
- 1Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - Tapio Visakorpi
- 1Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - G. Steven Bova
- 1Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| |
Collapse
|
7
|
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O’Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS. The evolutionary history of lethal metastatic prostate cancer. Nature 2015; 520:353-357. [PMID: 25830880 PMCID: PMC4413032 DOI: 10.1038/nature14347] [Citation(s) in RCA: 954] [Impact Index Per Article: 106.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2014] [Accepted: 02/23/2015] [Indexed: 02/07/2023]
Abstract
Cancers emerge from an ongoing Darwinian evolutionary process, often leading to multiple competing subclones within a single primary tumour. This evolutionary process culminates in the formation of metastases, which is the cause of 90% of cancer-related deaths. However, despite its clinical importance, little is known about the principles governing the dissemination of cancer cells to distant organs. Although the hypothesis that each metastasis originates from a single tumour cell is generally supported, recent studies using mouse models of cancer demonstrated the existence of polyclonal seeding from and interclonal cooperation between multiple subclones. Here we sought definitive evidence for the existence of polyclonal seeding in human malignancy and to establish the clonal relationship among different metastases in the context of androgen-deprived metastatic prostate cancer. Using whole-genome sequencing, we characterized multiple metastases arising from prostate tumours in ten patients. Integrated analyses of subclonal architecture revealed the patterns of metastatic spread in unprecedented detail. Metastasis-to-metastasis spread was found to be common, either through de novo monoclonal seeding of daughter metastases or, in five cases, through the transfer of multiple tumour clones between metastatic sites. Lesions affecting tumour suppressor genes usually occur as single events, whereas mutations in genes involved in androgen receptor signalling commonly involve multiple, convergent events in different metastases. Our results elucidate in detail the complex patterns of metastatic spread and further our understanding of the development of resistance to androgen-deprivation therapy in prostate cancer.
Collapse
Affiliation(s)
- Gunes Gundem
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - Peter Van Loo
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
- Department of Human Genetics, KU Leuven, Herestraat 49 Box 602, B-3000 Leuven, Belgium
- Cancer Research UK London Research Institute, London, UK
| | - Barbara Kremeyer
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | | | - Jose M.C. Tubio
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | | | - Daniel S. Brewer
- Norwich Medical School and Department of Biological Sciences, University of East Anglia, Norwich, UK
| | - Heini M.L. Kallio
- Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - Gunilla Högnäs
- Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - Matti Annala
- Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - Kati Kivinummi
- Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - Victoria Goody
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - Calli Latimer
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - Sarah O’Meara
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - Kevin J. Dawson
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - William Isaacs
- The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Michael R Emmert-Buck
- Laboratory of Pathology, National Cancer Institute, National Institutes of Health, MD, USA
| | - Matti Nykter
- Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - Christopher Foster
- University of Liverpool and HCA Pathology Laboratories, London, UK
- Senior Principal Investigators of the Cancer Research UK funded ICGC Prostate Cancer Project
| | - Zsofia Kote-Jarai
- Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, UK
| | - Douglas Easton
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
- Senior Principal Investigators of the Cancer Research UK funded ICGC Prostate Cancer Project
| | - Hayley C. Whitaker
- Uro-oncology Research Group, Cancer Research UK Cambridge Research Institute, Cambridge, UK
| | | | - David E. Neal
- Uro-oncology Research Group, Cancer Research UK Cambridge Research Institute, Cambridge, UK
- Department of Surgical Oncology, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK
- Senior Principal Investigators of the Cancer Research UK funded ICGC Prostate Cancer Project
| | - Colin S. Cooper
- Norwich Medical School and Department of Biological Sciences, University of East Anglia, Norwich, UK
- Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, UK
- Senior Principal Investigators of the Cancer Research UK funded ICGC Prostate Cancer Project
| | - Rosalind A. Eeles
- Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, UK
- Royal Marsden NHS Foundation Trust, London and Sutton, UK
- Senior Principal Investigators of the Cancer Research UK funded ICGC Prostate Cancer Project
| | - Tapio Visakorpi
- Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | | | - Ultan McDermott
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
- Senior Principal Investigators of the Cancer Research UK funded ICGC Prostate Cancer Project
| | - David C. Wedge
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - G. Steven Bova
- Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
- Senior Principal Investigators of the Cancer Research UK funded ICGC Prostate Cancer Project
| |
Collapse
|
8
|
Arjonen A, Kaukonen R, Mattila E, Rouhi P, Högnäs G, Sihto H, Miller BW, Morton JP, Bucher E, Taimen P, Virtakoivu R, Cao Y, Sansom OJ, Joensuu H, Ivaska J. Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis. J Clin Invest 2014; 124:1069-82. [PMID: 24487586 PMCID: PMC3934176 DOI: 10.1172/jci67280] [Citation(s) in RCA: 116] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2013] [Accepted: 11/14/2013] [Indexed: 02/04/2023] Open
Abstract
Mutations of the tumor suppressor TP53 are present in many forms of human cancer and are associated with increased tumor cell invasion and metastasis. Several mechanisms have been identified for promoting dissemination of cancer cells with TP53 mutations, including increased targeting of integrins to the plasma membrane. Here, we demonstrate a role for the filopodia-inducing motor protein Myosin-X (Myo10) in mutant p53-driven cancer invasion. Analysis of gene expression profiles from 2 breast cancer data sets revealed that MYO10 was highly expressed in aggressive cancer subtypes. Myo10 was required for breast cancer cell invasion and dissemination in multiple cancer cell lines and murine models of cancer metastasis. Evaluation of a Myo10 mutant without the integrin-binding domain revealed that the ability of Myo10 to transport β₁ integrins to the filopodia tip is required for invasion. Introduction of mutant p53 promoted Myo10 expression in cancer cells and pancreatic ductal adenocarcinoma in mice, whereas suppression of endogenous mutant p53 attenuated Myo10 levels and cell invasion. In clinical breast carcinomas, Myo10 was predominantly expressed at the invasive edges and correlated with the presence of TP53 mutations and poor prognosis. These data indicate that Myo10 upregulation in mutant p53-driven cancers is necessary for invasion and that plasma-membrane protrusions, such as filopodia, may serve as specialized metastatic engines.
Collapse
Affiliation(s)
- Antti Arjonen
- Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland.
Turku Centre for Biotechnology, University of Turku, Turku, Finland.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Laboratory of Molecular Oncology, University of Helsinki, Biomedicum, Helsinki, Finland.
CR-UK Beatson Institute for Cancer Research, University of Glasgow, Glasgow, United Kingdom.
Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Department of Cardiovascular Sciences, University of Leicester, and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom.
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland
| | - Riina Kaukonen
- Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland.
Turku Centre for Biotechnology, University of Turku, Turku, Finland.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Laboratory of Molecular Oncology, University of Helsinki, Biomedicum, Helsinki, Finland.
CR-UK Beatson Institute for Cancer Research, University of Glasgow, Glasgow, United Kingdom.
Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Department of Cardiovascular Sciences, University of Leicester, and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom.
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland
| | - Elina Mattila
- Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland.
Turku Centre for Biotechnology, University of Turku, Turku, Finland.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Laboratory of Molecular Oncology, University of Helsinki, Biomedicum, Helsinki, Finland.
CR-UK Beatson Institute for Cancer Research, University of Glasgow, Glasgow, United Kingdom.
Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Department of Cardiovascular Sciences, University of Leicester, and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom.
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland
| | - Pegah Rouhi
- Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland.
Turku Centre for Biotechnology, University of Turku, Turku, Finland.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Laboratory of Molecular Oncology, University of Helsinki, Biomedicum, Helsinki, Finland.
CR-UK Beatson Institute for Cancer Research, University of Glasgow, Glasgow, United Kingdom.
Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Department of Cardiovascular Sciences, University of Leicester, and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom.
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland
| | - Gunilla Högnäs
- Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland.
Turku Centre for Biotechnology, University of Turku, Turku, Finland.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Laboratory of Molecular Oncology, University of Helsinki, Biomedicum, Helsinki, Finland.
CR-UK Beatson Institute for Cancer Research, University of Glasgow, Glasgow, United Kingdom.
Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Department of Cardiovascular Sciences, University of Leicester, and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom.
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland
| | - Harri Sihto
- Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland.
Turku Centre for Biotechnology, University of Turku, Turku, Finland.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Laboratory of Molecular Oncology, University of Helsinki, Biomedicum, Helsinki, Finland.
CR-UK Beatson Institute for Cancer Research, University of Glasgow, Glasgow, United Kingdom.
Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Department of Cardiovascular Sciences, University of Leicester, and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom.
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland
| | - Bryan W. Miller
- Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland.
Turku Centre for Biotechnology, University of Turku, Turku, Finland.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Laboratory of Molecular Oncology, University of Helsinki, Biomedicum, Helsinki, Finland.
CR-UK Beatson Institute for Cancer Research, University of Glasgow, Glasgow, United Kingdom.
Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Department of Cardiovascular Sciences, University of Leicester, and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom.
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland
| | - Jennifer P. Morton
- Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland.
Turku Centre for Biotechnology, University of Turku, Turku, Finland.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Laboratory of Molecular Oncology, University of Helsinki, Biomedicum, Helsinki, Finland.
CR-UK Beatson Institute for Cancer Research, University of Glasgow, Glasgow, United Kingdom.
Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Department of Cardiovascular Sciences, University of Leicester, and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom.
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland
| | - Elmar Bucher
- Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland.
Turku Centre for Biotechnology, University of Turku, Turku, Finland.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Laboratory of Molecular Oncology, University of Helsinki, Biomedicum, Helsinki, Finland.
CR-UK Beatson Institute for Cancer Research, University of Glasgow, Glasgow, United Kingdom.
Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Department of Cardiovascular Sciences, University of Leicester, and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom.
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland
| | - Pekka Taimen
- Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland.
Turku Centre for Biotechnology, University of Turku, Turku, Finland.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Laboratory of Molecular Oncology, University of Helsinki, Biomedicum, Helsinki, Finland.
CR-UK Beatson Institute for Cancer Research, University of Glasgow, Glasgow, United Kingdom.
Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Department of Cardiovascular Sciences, University of Leicester, and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom.
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland
| | - Reetta Virtakoivu
- Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland.
Turku Centre for Biotechnology, University of Turku, Turku, Finland.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Laboratory of Molecular Oncology, University of Helsinki, Biomedicum, Helsinki, Finland.
CR-UK Beatson Institute for Cancer Research, University of Glasgow, Glasgow, United Kingdom.
Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Department of Cardiovascular Sciences, University of Leicester, and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom.
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland
| | - Yihai Cao
- Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland.
Turku Centre for Biotechnology, University of Turku, Turku, Finland.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Laboratory of Molecular Oncology, University of Helsinki, Biomedicum, Helsinki, Finland.
CR-UK Beatson Institute for Cancer Research, University of Glasgow, Glasgow, United Kingdom.
Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Department of Cardiovascular Sciences, University of Leicester, and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom.
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland
| | - Owen J. Sansom
- Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland.
Turku Centre for Biotechnology, University of Turku, Turku, Finland.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Laboratory of Molecular Oncology, University of Helsinki, Biomedicum, Helsinki, Finland.
CR-UK Beatson Institute for Cancer Research, University of Glasgow, Glasgow, United Kingdom.
Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Department of Cardiovascular Sciences, University of Leicester, and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom.
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland
| | - Heikki Joensuu
- Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland.
Turku Centre for Biotechnology, University of Turku, Turku, Finland.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Laboratory of Molecular Oncology, University of Helsinki, Biomedicum, Helsinki, Finland.
CR-UK Beatson Institute for Cancer Research, University of Glasgow, Glasgow, United Kingdom.
Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Department of Cardiovascular Sciences, University of Leicester, and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom.
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland
| | - Johanna Ivaska
- Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland.
Turku Centre for Biotechnology, University of Turku, Turku, Finland.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Laboratory of Molecular Oncology, University of Helsinki, Biomedicum, Helsinki, Finland.
CR-UK Beatson Institute for Cancer Research, University of Glasgow, Glasgow, United Kingdom.
Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Department of Cardiovascular Sciences, University of Leicester, and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom.
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland
| |
Collapse
|
9
|
Vuoriluoto K, Högnäs G, Meller P, Lehti K, Ivaska J. Syndecan-1 and -4 differentially regulate oncogenic K-ras dependent cell invasion into collagen through α2β1 integrin and MT1-MMP. Matrix Biol 2011; 30:207-17. [PMID: 21414405 DOI: 10.1016/j.matbio.2011.03.003] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2010] [Revised: 02/24/2011] [Accepted: 03/04/2011] [Indexed: 01/05/2023]
Abstract
Syndecans function as co-receptors for integrins on different matrixes. Recently, syndecan-1 has been shown to be important for α2β1 integrin-mediated adhesion to collagen in tumor cells by regulating cell adhesion and migration on two-dimensional collagen. However, the function of syndecans in supporting α2β1 integrin interactions with three-dimensional (3D) collagen is less well studied. Using loss-of-function and overexpression experiments we show that in 3D collagen syndecan-4 supports α2β1-mediated collagen matrix contraction. Cell invasion through type I collagen containing 3D extracellular matrix (ECM) is driven by α2β1 integrin and membrane type-1 matrix metalloproteinase (MT1-MMP). Here we show that mutational activation of K-ras correlates with increased expression of α2β1 integrin, MT1-MMP, syndecan-1, and syndecan-4. While K-ras-induced α2β1 integrin and MT1-MMP are positive regulators of invasion, silencing and overexpression of syndecans demonstrate that these proteins inhibit cell invasion into collagen. Taken together, these data demonstrate the existence of a complex interplay between integrin α2β1, MT1-MMP, and syndecans in the invasion of K-ras mutant cells in 3D collagen that may represent a mechanism by which tumor cells become more invasive and metastatic.
Collapse
|
10
|
Högnäs G, Heyer H, Falk M. Book reviews. METRIKA 1994. [DOI: 10.1007/bf01895305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Högnäs G. Sequences of Random Transformations. Theory Probab Appl 1993. [DOI: 10.1137/1137010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|